Dr. Kinoshita is evaluating the immunobiology of multi-antigen specific T-cell therapy infused to patients to reduce the two most common causes of morbidity and mortality following stem cell transplant—cancer relapse and infection.
published research
Kinoshita H, Mandava M, Jensen-Wachspress MA, Lang H, Joy E, Tanna J, McCann CD, O’Brien S, Burnett S, Shibli A, Hoq F, Bhatia M, Hanley PJ, Dávila Saldaña BJ, Mahadeo KM, Bollard CM, Keller MD, Abraham AA. Outcomes following posttransplant viral-specific T-cell therapy in patients with sickle cell disease. Blood Adv. 2022.